Список проголосовавших за комментарий " On The Wires<ul><li>Audentes Therapeutics (<strong>BOLD</strong>) announced the commencement of LUSTRO, a prospective study designed to characterize the disease course in patients living with Crigler-Najjar Syndrome. LUSTRO will evaluate subjects prior to potential enrollment in VALENS, the planned Phase 1/2 clinical study to evaluate the safety and preliminary efficacy of AT342, the Audentes product candidate being developed to treat Crigler-Najjar Syndrome.</li><li>Community Healthcare Trust (<strong>CHCT</strong>) announced that its Chairman, CEO and President Timothy Wallace entered into a 10b5-1 purchase plan to acquire shares of the Company's common stock consistent with certain timing, volume and price limitations. The Plan replaces Mr. Wallace's 10b5-1 trading plan dated February 29, 2016, which expired on December 31, 2016. The Plan was entered into on February 27, 2017 and will become effective April 3, 2017. Under the Plan, Wallace will be able to purchase up to the lesser of $2 mln or 100k shares of its common stock. </li><li>Aytu BioScience (<strong>AYTU</strong>) announced the successful completion of its tender offer to amend and exercise certain categories of existing warrants. Co received $2.2 million from exercise of warrants. Proceeds are anticipated to be used for working capital and general corporate purposes.</li><li>GRAIL in.c announced that it has raised over $900 million through the first close of its previously announced Series B financing which was led by ARCH Venture Partners and includes Johnson & Johnson Innovation (<strong>JNJ</strong>) as the largest investor in the financing. The initial close also includes world-class strategic pharmaceutical, technology and financial investors. In addition to ARCH Venture Partners and Johnson & Johnson Innovation, the strategic investors participating in the first close include Amazon (<strong>AMZN</strong>), Bristol-Myers Squibb (<strong>BMY</strong>), Celgene (<strong>CELG</strong>), McKesson Ventures (<strong>CMK</strong>), Merck (<strong>MRK</strong>), Tencent Holdings (<strong>TCEHY</strong>) and Varian Medical Systems (<strong>VAR</strong>). GRAIL will use the proceeds of the financing for continued product development and validation of blood tests for early-stage cancer detection, including the previously announced Circulating Cell-free Genome Atlas study and other large-scale clinical trials that are expected to enroll hundreds of thousands of patients. Some of the proceeds were used to repurchase a portion of Illumina's (<strong>ILMN</strong>) stake in GRAIL such that Illumina now owns slightly less than 20 percent of the Company. Going forward, Illumina will reflect its remaining ownership of GRAIL as a cost-method investment in Illumina's financial statements.</li></ul>"